Home/Filings/4/0001193805-24-000245

4//SEC Filing

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 4

Accession 0001193805-24-000245

CIK 0001374690other

View on SEC.gov Company Profile

Filed

Feb 15, 7:00 PM ET

Accepted

Feb 16, 2:37 PM ET

Size

37.6 KB

Accession

0001193805-24-000245

Insider Transaction Report

Form 4

Period: 2024-02-16

Larimar Therapeutics, Inc.LRMR

DEERFIELD MANAGEMENT CO /NY

Director10% OwnerOther

Transactions

Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,406 total(indirect: Through Deerfield Private Design Fund IV, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,205$12,499,992→ 4,207,982 total(indirect: Through Deerfield Partners, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,389 total(indirect: Through Deerfield Private Design Fund III, L.P.)

Holdings

Common Stock
(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
4,721,197

Deerfield Mgmt IV, L.P.

Director10% OwnerOther

Transactions

Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,406 total(indirect: Through Deerfield Private Design Fund IV, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,389 total(indirect: Through Deerfield Private Design Fund III, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,205$12,499,992→ 4,207,982 total(indirect: Through Deerfield Partners, L.P.)

Holdings

Common Stock
(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
4,721,197

DEERFIELD CAPITAL LP

Director10% OwnerOther

Transactions

Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,389 total(indirect: Through Deerfield Private Design Fund III, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,406 total(indirect: Through Deerfield Private Design Fund IV, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,205$12,499,992→ 4,207,982 total(indirect: Through Deerfield Partners, L.P.)

Holdings

Common Stock
(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
4,721,197

Deerfield Mgmt III, L.P.

Director10% OwnerOther

Transactions

Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,389 total(indirect: Through Deerfield Private Design Fund III, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,205$12,499,992→ 4,207,982 total(indirect: Through Deerfield Partners, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,406 total(indirect: Through Deerfield Private Design Fund IV, L.P.)

Holdings

Common Stock
(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
4,721,197

Flynn James E

Director10% OwnerOther

Transactions

Purchase
Common Stock
2024-02-16$8.74/sh+1,430,205$12,499,992→ 4,207,982 total(indirect: Through Deerfield Partners, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,406 total(indirect: Through Deerfield Private Design Fund IV, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,389 total(indirect: Through Deerfield Private Design Fund III, L.P.)

Holdings

Common Stock
(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
4,721,197

Deerfield Mgmt HIF, L.P.

Director10% OwnerOther

Transactions

Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,389 total(indirect: Through Deerfield Private Design Fund III, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,406 total(indirect: Through Deerfield Private Design Fund IV, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,205$12,499,992→ 4,207,982 total(indirect: Through Deerfield Partners, L.P.)

Holdings

Common Stock
(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
4,721,197

Deerfield Private Design Fund III, L.P.

Director10% OwnerOther

Transactions

Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,389 total(indirect: Through Deerfield Private Design Fund III, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,205$12,499,992→ 4,207,982 total(indirect: Through Deerfield Partners, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,406 total(indirect: Through Deerfield Private Design Fund IV, L.P.)

Holdings

Common Stock
(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
4,721,197

Deerfield Private Design Fund IV, L.P.

Director10% OwnerOther

Transactions

Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,389 total(indirect: Through Deerfield Private Design Fund III, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,406 total(indirect: Through Deerfield Private Design Fund IV, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,205$12,499,992→ 4,207,982 total(indirect: Through Deerfield Partners, L.P.)

Holdings

Common Stock
(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
4,721,197

DEERFIELD PARTNERS, LP

Director10% OwnerOther

Transactions

Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,406 total(indirect: Through Deerfield Private Design Fund IV, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,389 total(indirect: Through Deerfield Private Design Fund III, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,205$12,499,992→ 4,207,982 total(indirect: Through Deerfield Partners, L.P.)

Holdings

Common Stock
(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
4,721,197

Deerfield Healthcare Innovations Fund, L.P.

Director10% OwnerOther

Transactions

Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,406 total(indirect: Through Deerfield Private Design Fund IV, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,205$12,499,992→ 4,207,982 total(indirect: Through Deerfield Partners, L.P.)
Purchase
Common Stock
2024-02-16$8.74/sh+1,430,206$12,500,000→ 6,151,389 total(indirect: Through Deerfield Private Design Fund III, L.P.)

Holdings

Common Stock
(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
4,721,197

Footnotes (2)

[F1]This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. ("Fund IV"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. ("Deerfield HIF"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. ("Deerfield Partners"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the "Funds"). James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P.
[F2]In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Documents

2 files

Issuer

Larimar Therapeutics, Inc.

CIK 0001374690

→

Entity typeother

IncorporatedDE

Related Parties

filerCIK 0001009258

Filing Metadata

Form type: 4
Filed: Feb 15, 7:00 PM ET
Accepted: Feb 16, 2:37 PM ET
Size: 37.6 KB

View on SEC.gov